Where does Alternative Gene Expression S.L. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Alternative Gene Expression S.L. ranks #44,633 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Alternative Gene Expression S.L. hold?

Alternative Gene Expression S.L. holds 5 US utility patents granted between 2017 and 2025, spanning 6 technology areas.

What is Alternative Gene Expression S.L.'s Innovation Score?

Alternative Gene Expression S.L. has an Innovation Score of 28.5 out of 100 (27th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Alternative Gene Expression S.L.'s patent grant rate increasing or decreasing?

Alternative Gene Expression S.L.'s recent grant velocity is -67% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Alternative Gene Expression S.L.'s patents?

Alternative Gene Expression S.L.'s patents average 11.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Alternative Gene Expression S.L. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Alternative Gene Expression S.L.

Q: What technology areas does Alternative Gene Expression S.L. focus on?

Alternative Gene Expression S.L.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 4 patents, ranking #2,122 of 4,144 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Alternative ranks #44,633 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.

#44,633
of 49,997 US assignees by volume: 27th percentile
by Innovation Score (28.5/100): 11.6
avg claims per patent: -67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R44633 · Foreign Corporation #44,633 · 5 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 5 grants
LOWER-Q #44,633/49,997
PHOTO-FINISH ALT Innovations
CPC-NARROW C12N · 6 areas
INNOV-THIN 28.5/100
CLAIMS-PAR 11.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: ALT Innovations LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Alternative’s 28.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (22%) Velocity 6.7 pts (23%) Breadth 8.7 pts (30%) Claim depth 7.0 pts (24%)

Qualcomm Incorporated · highest

85
Alternative Gene… · this assignee

28
3D Lighting… · lowest

7

What this shows Alternative's Innovation Score is 28.5/100 (27th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Alternative?

Each dot is one of Alternative’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Alternative’s own 11.6 claims/patent is ABOVE the 11.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Alternative vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Alternative's grants concentrate

Alternative Gene Expression S.L. is a focused PatentsView assignee: 6 CPC subclasses with 80% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2017. By volume, Alternative sits between ALT Innovations LLC and AM Conservation Group.

Alternative's three-year grant acceleration

Alternative Gene Expression S.L. shows 1 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

ALT Innovations

5
Altana

5
Altatech Semicond…

5
Altergy Systems

5
Altus Partners

5
Aludesign S P A

5
Aluminum Architec…

5
AM Conservation G…

5
Alternative Gene… ◀

5

What this shows Alternative holds 5 patents at rank #44,506, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Alternative

By rank, the assignees closest to #44,506 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Alternative's primary technology class.

Alternative's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 27th percentile higher than 27% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Alternative Gene Expression S.L. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	20.0%
2018	2	40.0%
2022	1	20.0%
2025partial year	1	20.0%

Which technologies does Alternative Gene Expression S.L. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 3

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

C07K - Peptides 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Alternative Gene Expression S.L.'s patent record in context - here's where to go next.

Alternative Gene Expression S.L.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 80% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #44,633 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Alternative Gene Expression S.L. against ALT Innovations LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.